Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for prurigo nodularis in Japan
jRCT2080225104Phase 3Completed
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in prurigo nodularis (PN) comparing Dupilumab with Placebo / control (2 arms). Started Mar 2020; status: completed.
02
Drugs
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on jRCT2080225104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225104.